CUE BIOPHARMA INC's ticker is CUE and the CUSIP is 22978P106. A total of 78 filers reported holding CUE BIOPHARMA INC in Q2 2023. The put-call ratio across all filers is 0.49 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $221,587 | -7.5% | 96,342 | +46.7% | 0.00% | – |
| Q2 2023 | $239,677 | -49.3% | 65,665 | -50.5% | 0.00% | – |
| Q1 2023 | $473,150 | +464.7% | 132,535 | +350.8% | 0.00% | – |
| Q4 2022 | $83,790 | -18.7% | 29,400 | -36.5% | 0.00% | – |
| Q3 2022 | $103,000 | -77.3% | 46,273 | -74.6% | 0.00% | – |
| Q2 2022 | $453,000 | -62.5% | 182,011 | -26.5% | 0.00% | – |
| Q1 2022 | $1,208,000 | -68.7% | 247,520 | -27.5% | 0.00% | – |
| Q4 2021 | $3,860,000 | +83.0% | 341,408 | +135.9% | 0.00% | – |
| Q3 2021 | $2,109,000 | +24.4% | 144,707 | -0.6% | 0.00% | – |
| Q2 2021 | $1,696,000 | -10.2% | 145,514 | -6.0% | 0.00% | – |
| Q1 2021 | $1,888,000 | -9.7% | 154,757 | -7.4% | 0.00% | – |
| Q4 2020 | $2,090,000 | +80.0% | 167,076 | +116.7% | 0.00% | – |
| Q3 2020 | $1,161,000 | -64.0% | 77,100 | -41.3% | 0.00% | – |
| Q2 2020 | $3,223,000 | +879.6% | 131,446 | +466.6% | 0.00% | – |
| Q1 2020 | $329,000 | – | 23,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 829,042 | $9,376,000 | 5.61% |
| P.A.W. CAPITAL CORP | 120,000 | $1,357,000 | 1.24% |
| Nantahala Capital Management | 2,539,700 | $28,724,000 | 1.01% |
| Slate Path Capital LP | 1,483,619 | $16,780,000 | 0.88% |
| SANDERS MORRIS HARRIS LLC | 359,113 | $4,416,000 | 0.76% |
| APOGEM CAPITAL LLC | 62,295 | $705,000 | 0.46% |
| Robertson Stephens Wealth Management, LLC | 478,500 | $5,411,000 | 0.46% |
| Bleichroeder LP | 200,000 | $2,262,000 | 0.35% |
| ADVISORY RESEARCH INC | 257,225 | $2,909,000 | 0.23% |
| Granite Point Capital Management, L.P. | 110,000 | $1,244,000 | 0.21% |